Tim Wartewig
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Activation of gp130 signaling in T cells drives TH17-mediated multi-organ autoimmunity.
Journal: Science signaling
Published: February 20, 2024
The fusion oncogene VAV1-MYO1F triggers aberrant T-cell receptor signaling in vivo and drives peripheral T-cell lymphoma in mice.
Journal: European journal of immunology
Published: August 22, 2022
PD-1 instructs a tumor-suppressive metabolic program that restricts glycolysis and restrains AP-1 activity in T cell lymphoma.
Journal: Nature cancer
Published: August 22, 2022
Executioner caspases 3 and 7 are dispensable for intestinal epithelium turnover and homeostasis at steady state.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: December 19, 2021
Keratinocyte-intrinsic BCL10/MALT1 activity initiates and amplifies psoriasiform skin inflammation.
Journal: Science immunology
Published: November 26, 2021
The uric acid crystal receptor Clec12A potentiates type I interferon responses.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: August 28, 2019
PD-1 Tumor Suppressor Signaling in T Cell Lymphomas.
Journal: Trends in immunology
Published: January 21, 2019
Foxp1 controls mature B cell survival and the development of follicular and B-1 B cells.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 07, 2018
Erratum: PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.
Journal: Nature
Published: November 30, 2017
PD-1 is a haploinsufficient suppressor of T cell lymphomagenesis.
Journal: Nature
Published: February 16, 2017
Showing 1-11 of 11
Last Updated: 09/26/2026